Aims: To evaluate asthma care in the emergency department (ED), including use of pulmonary function testing (PFT) and how patients are treated when discharged.
Introduction
Asthma is a chronic condition often associated with acute exacerbations, especially when not well controlled. Acute asthma often necessitates care in the emergency department (ED) and may be life-threatening. [1] [2] [3] [4] Acute asthma affects 10% of patients with asthma in Western Europe and 23% of those with asthma in the US, annually. ED visits not only make a substantial contribution to healthcare costs worldwide, but are also markers of increased morbidity, along with suboptimal access to care, treatment adherence, and/or selfmanagement. [5] [6] [7] [8] [9] [10] Effective guideline-driven management of diagnostic testing in the ED and prescription of asthma controller medications upon ED discharge could decrease the need for urgent care.
Asthma treatment guidelines issued by the Global Initiative for Asthma (GINA) and other consensus panels state that objective pulmonary function testing (PFT) plays a central role in evaluating and managing acute asthma exacerbations. [11] [12] [13] [14] [15] [16] [17] GINA guidelines specify that functional assessments such as spirometry, peak expiratory flow (PEF) measurement, and oxygen saturation measurements with oximetry, to assess the severity of an asthma exacerbation, should be performed ideally prior to, but hopefully concurrently with, any intervention instituted in the ED. Such assessments should be repeated one hour after initial treatment and then at 1-to 2-hour intervals until there is a clear response to treatment and a decision is reached about patient disposition. 11 GINA guidelines recommend that the care of patients discharged with an acute asthma attack should generally include: 1) a minimum 3-to 7-day course of oral corticosteroids; 2) initial or continued use of controller therapy; 3) review of inhaler technique and use of peak flow meter; 4) identification of potential triggers of exacerbations; 5) provision of a written action plan for prevention of future exacerbations; and 6) encouragement to contact a physician within one week after discharge for a follow-up appointment. 11 Treatment programs that adhere to asthma management guidelines and a high continuity of care can significantly reduce ED visits, 15 ,17 yet information on guideline adherence to PFT and prescribing practices for acute asthma exacerbations in the ED is limited. The aim of the Multinational Acute asthma Management, Burden, and Outcomes (MAMBO) study was to understand current approaches to acute asthma care in the ED around the world. This manuscript describes the frequency with which PFT was performed, along with the asthma treatment prescribed for patients upon ED discharge.
Methods

Study design
The MAMBO study was a multinational, Internet-based observational survey of acute asthma care conducted in Australia, Canada, Mexico, Italy, France, Spain, and the UK. This study was solely an audit of patient chart records undertaken by the treating physician, and was not experimental or interventional. Data were captured in an anonymised form, and thus Institutional Review Board approval was not required. The study did not require ethics approval because it was designed to describe the standard approach to care for acute asthma in the ED, and there were no confidentiality issues identified given the non-nominal nature of the data entry.
Study population
Healthcare practitioners (HCPs) who treated >10 patients with asthma per year in the ED and who were not currently involved in any clinical trials for asthma were eligible for participation. HCPs were identified and recruited from a worldwide panel of physicians who had previously expressed interest in participating in asthma research; the panel represented different types of physician based in different countries and regions within those countries. Physicians were recruited through clinical websites and other methods operated by our Internet service provider to select physicians interested in market research; identities were validated. Approximately 4,000 eligible physicians were identified and invited to participate in this study.
A feasibility assessment focused on the ability to collect the desired patient data was conducted during the initial planning phase of the study (primarily via interview with a few HCPs from each country). The original patient target number of approx 1200 total patients (approx 170 per country) from 42 HCPs per country was determined appropriate for statistical testing of differences across countries. These numbers were exceeded and data were collected on 1,370 patients, since most physicians elected to provide data on more than the minimum number of patients requested. The pre-specified target numbers were met over a 6.5 week period. HCPs were remunerated for their participation in the survey.
Respondents provided information extracted from the medical records of the most recent four to six consecutive, unique patients they had treated for acute asthma who met the study inclusion criteria; patients were aged 15-70 years old and were treated in the ED for a primary diagnosis of an acute asthma exacerbation from January 1st to December 31st, 2006. Patients with a primary diagnosis of chronic obstructive pulmonary disease (COPD), bronchiectasis, bronchiolitis, cystic fibrosis, lung cancer, pneumonia, or other airway infections were excluded.
Survey instrument
The survey instrument (see online Appendix at www.thepcrj.org) was developed by Adelphi Real World (Bollington, UK), a global health-services research group. It was translated into the primary language(s) of each country, then back-translated into English for tabulation and analysis. The instrument was tested before the study started to ensure reliability (routing, completeness). Final routing (i.e. when a respondent answers a question and is routed to the next applicable question), validation and consistency checks were conducted to ensure data were within range and routed to the correct field. A secure Internet website was established for uploading of data. To ensure the quality of the data, internal validation checks were written into the survey programme (e.g. acceptable drug doses, values for clinical results, etc). Similar approaches utilising electronic data capture have been reported for other published studies. [18] [19] [20] Participating HCPs entered information directly into the survey instrument. Patient data included demographic and clinical information, such as physician-assessed asthma severity, the presence of co-morbidities, prescription medications self-administered within 24 hours before presentation to the ED, and mode of arrival. Patient outcomes examined were receipt of certain prescribed medications/referrals upon discharge from the ED setting by country and by history of self-administering these medications within 24 hours of presenting to the ED. All data were made anonymous and age bands rather than dates of birth recorded to prevent patient identification.
Continuous data monitoring revealed the need for slight modification of the survey instrument during the early stages of data collection. Invalid values submitted for a question on asthma admission codes, intended to signify severity of the exacerbation, indicated a misinterpretation of the question and need for adjustment. The initial question was rewritten to solicit the physician-perceived severity of the exacerbation. As a result, the severity of the exacerbation for data reported prior to the modification could not be obtained and patients were reported as unclassified.
Statistical analysis
Patients with a secondary diagnosis of COPD or those who spent >12 hours in the ED were excluded. Descriptive data were summarised as mean (SD), or in box-whisker plots, and categorical data as number (%). Categorical data between countries and patients receiving (versus not receiving) PFT were compared using Fisher's exact tests and χ 2 tests; continuous data were compared using Student's t tests. Statistical testing was two-sided at α=.05. Analyses were conducted using STATA 9.2 Special Edition (StataCorp, College Station, TX). Approximately 50% of patients had mild or moderate exacerbations by physician assessments; 54% of patients were female; and 39% were smokers (see Table 1 ).
Results
Data
Pulmonary function testing (PFT)
Fewer than half (n=527, 49%) of the patients underwent objective measurement of airflow obstruction in the ED, with wide variation across countries (see Table 2 and Figure 1 ). Lung function was less commonly assessed in Mexico, Spain, and Italy, and more commonly assessed in Australia, the UK, and France. Among patients who had PFT, 77% had a PEF measured, 11% an FEV 1, and 12% had both PEF and FEV1 measured. Patients who completed PFT were significantly more likely to have pulse oximetry ( Patients who completed PFT were more likely to receive a combination of asthma treatments compared with monotherapy (chiefly β-agonists), and were less likely to receive no asthma medications. Less than 60% of all patients received guideline-recommended ED therapy consisting of a bronchodilator, corticosteroid (oral or inhaled), and supplemental oxygen (59% PFT vs 45% no PFT; p< 0.001). Similar trends were evident for patients receiving a bronchodilator (95% PFT vs 90% no PFT; p<0.001), or a bronchodilator plus a corticosteroid (81% PFT vs 72% no PFT; p<0.001).
Patients who were hospitalised were more likely to have received PFT (35% vs 29%; p= 0.039) ( Figure 2 ). A total of 17% of patients without PFT were discharged to the community without referral to a specialist, compared with 9% of those who had received PFT (p<0.0001).
Discharge medications
Survey data were obtained on the type of medications taken within 24 hours before presentation to the ED, as reported by patients. A total of 549 (50.9%) patients self-administered prescription asthma medications before presenting to the ED. Of these, 74% used short-acting β-agonist (SABA) "rescue" agents; 30% inhaled corticosteroids (ICS) monotherapy; 22.0% a combination of ICS and long-acting β-adrenergic agonist (ICS/LABAs); 18.2% anti-cholinergics; 13.7% LABAs alone; and 13.1% oral corticosteroids. Other therapies included theophylline and leukotriene receptor antagonists (LTRAs) in approximately 4% of patients and supplemental oxygen in <1% (many patients used more than one therapy). The proportions of patients using β-agonists ranged from 75.8% in Italy to 100% in France, self-administered ICS ranged from 33.3% in Mexico to 64.8% in Canada, and oral corticosteroids ranged from 6.6% in Canada to 21.0% in Italy. The proportions of patients using each of these medication classes at or before ED presentation were evenly distributed by asthma severity. Information on previous medication use was unavailable in 102 (9.5%) patients.
A total of 176 (17.7%) of 995 patients with available data did not receive a prescription for an asthma medication upon discharge from the ED (Table 2 ), ranging from 6.3% in the UK to 21.0% in Australia. Patients who did receive discharge medications were significantly more likely to be male (p=0.02), to have more severe disease based upon physician assessment of severity (p<0.0001), and to have been seen by a pulmonologist/chest physician rather than an ED physician (p<0.0001).
Of all patients discharged with a prescription for asthma medication, 73.7% received a controller agent, including ICS, ICS/LABA, and/or LTRAs. Country-specific proportions ranged from 60.9% of patients in Mexico to 83.4% in Italy ( Figure 3 Most patients were discharged with a referral to a general practitioner (GP) (52.0%) or were admitted to the hospital (32.3%; Figure 4) . A further 12.8% were discharged without referral to a GP, (8.6% in Spain to 17.9% in Canada). Thirtyone patients (2.9%) relapsed to the ED and 10 (0.9%) died within 14 days after discharge from hospital. Approximately 24% of patients had been hospitalised within the six months prior to the documented ED visit.
Discussion
This study found poor adherence with guidelines that recommend objective PFT before and during ED visits for patients with acute asthma exacerbations. PFT was performed in less than half of the patients, suggesting that many practitioners rely on subjective signs and symptoms and patient self-report rather than objective indices in order to evaluate exacerbation severity and make management decisions. This is contrary to guideline recommendations indicating that a critical component of managing asthma exacerbations and guiding treatment is the ability of physicians to judge the severity of airflow obstruction and to treat patients adequately. 11 Patients treated in Australia, France, or the UK, younger patients, those with moderate exacerbations, those arriving via ambulance, and patients in university-affiliated hospitals and larger institutions were most likely to receive PFT. Pulmonologists and ED physicians were about equally likely to perform a PFT.
Patterns in the use of PFT observed in this study are consistent with published accounts. For example, a Spanish study showed that their country had the lowest proportion of HCPs conducting PFT, consistent with data from primary healthcare facilities in Spain where there was minimal adherence to guideline recommendations. 21 Results of a crosssectional survey of Canadian ED physicians also showed wide variations in use of objective measurements; 46% used FEV 1 "occasionally" and 26.7% used peak flow meters "occasionally". 22 In Canada, Jin et al. found that adherence to guidelines and use of objective lung function testing were related to physician specialty, with family physicians having the lowest rates. 23 A single-centre survey in Italy reported that 14% of adolescents with asthma had never had PFT performed. 24 Even in specialty asthma centres in the US, spirometry is not conducted routinely. 25 In this study, PEF was used more frequently than spirometry, perhaps because of ease of use and cost considerations. A standardised asthma management program in France resulted in a marked increase in PEF measurements from the first audit (19.1%) to the postintervention audit (88.1%, p<0.001). 26 Use of spirometry or PEF increased from 38% to 85% (p<0.01) in a hospital that implemented evidence-based strategies, whereas it decreased in the control hospital. 27 Effective training can be brief and inexpensive. 28 Clinicians are often not trained to perform spirometry and may have been less inclined to do so, potentially leading to biased results due to underperformance. Trained clinicians may acknowledge the inadequacy of treating without the benefit of underlying pulmonary function measurement.
In the MAMBO cohort, patients who underwent PFT had significantly more courses of therapy and received more medications than those who did not undergo PFT. It may be that those clinicians who were more likely to perform objective measurements were also more likely to treat patients according to guidelines. Patients perceived to have mild disease were less likely to have PFT and patients not having PFT were less likely to receive multiple therapies, suggesting that physician perception of asthma severity may influence management. Even patients with severe disease did not routinely undergo PFT, however.
In our study, suboptimal adherence to GINA guidelines for the discharge management of acute severe asthma across a number of different countries was documented, with nearly 1 in 5 patients not receiving a prescription for an asthma medication upon ED discharge, and 1 in 8 being discharged to their communities without a follow-up physician referral. Nearly 75% of patients self-administering asthma medications shortly before visiting the ED were using SABA rescue agents, compared with only 52% using ICS alone or in combination with a LABA. This may reflect patients' increased use of bronchodilators as their asthma symptoms worsen. 
Self-administered
Not self-administered † Based on 751 patients who were prescribed medication to take home and for whom information was available for self-administered medications.
All differences (self-administered vs. not) are significant p<0.05
Note: Cromones, theophylline, anti-IgE, and oxygen not shown. Patients in this study who had more severe exacerbations or were treated by a pulmonologist were significantly more likely to receive prescriptions for asthma medications at ED discharge, consistent with a French report showing that corticosteroid use in the ED was more likely in patients with more severe exacerbations. 3 A medical audit conducted in Spain reported that 17% of patients were discharged from the ED with no change to their usual treatment and that too many patients were discharged without a treatment plan. 29 Initiation of acute and chronic medications can potentially benefit patients at the time of ED discharge. 30, 31 Potential limitations of our study include not determining the reasons why HCPs did not perform PFT, or whether equipment for performing PFT was available at each site. Also, exclusion of HCPs involved in clinical trials may have resulted in underestimating the proportion of HCPs performing PFT. This study relied on patient self-report to assess asthma medication use within the 24 hours before ED admission, which may have skewed results towards use of therapies to alleviate acute symptoms. The study relied on HCP reports based on ED records which may not have captured accurately baseline factors such as co-morbidities, thereby potentially influencing discharge medications and instructions.
Response bias is another potential limitation. Eligible HCPs were invited to participate until target numbers were met and were therefore self-selected. We were unable to characterise participating physicians versus those who did not respond. Pre-specified quotas across specialties along with the range of countries were intended to increase the representativeness of the data. There was a low response rate in this study, but the large sample size and range of countries examined suggests the results are robust and truly reflect the current standard of acute asthma care. In addition, the study could not control for heterogeneity in the level of sub specialty training. There was also considerable variation in the healthcare systems in which patients were managed, with a higher proportion of GPs providing care in hospital ED settings and "general physicians" providing additional care for non-life-threatening asthma exacerbations in Australia.
Our findings extend previous research showing suboptimal knowledge of, adherence to, and adaptation of, asthma guidelines in general, and use of controller medications in particular, for the management of asthma in different countries. PFT was conducted infrequently in the ED setting and a substantial proportion of patients with acute exacerbations were discharged from the ED without adequate medications or referrals. There appears to be room for improvement in the care of asthma exacerbations, and in particular adherence to guidelines. Further studies are necessary to determine to what degree acute-care interventions aimed at improving asthma control help to enhance patient quality of life and reduce the global burden of asthma.
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This multinational study found poor adherence with international guidelines recommending use of pulmonary function testing and discharge management practices for patients seen in the ED for an acute asthma exacerbation. Challenges with physician recruitment, the absence of data on treatment algorithms, and limited data on pre-and post-emergent care limit the conclusions from this survey. Survey data from the patient and their GP could have helped to characterise pre-and post-emergent care. A study evaluating the impact of interventional strategies and usual care across homogeneous emergent settings would help to assess the impact of adherence to consensus guidelines on outcomes. Studies examining the drivers and barriers of objective testing, prescribing, and referral across specialties in an acute setting, are needed. 
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